IsentressTreatment for HIV Infection
Update: Isentress Now FDA Approved - October 12, 2007
Impending FDA Approval Decision on the First HIV Integrase Inhibitor Isentress Can Have Significant Impact for Patients
ANALYST AVAILABLE TO COMMENT ON THE MARKET FORECAST FOR THE DRUG
WALTHAM, Mass., October 12, 2007 /PRNewswire/ -- Dr. Sylvia Eash, Ph.D., analyst at Decision Resources, is available to discuss the impact of the Food and Drug Administration's (FDA) possible approval of Merck's Isentress, the first integrase inhibitor drug which blocks the ability of the HIV virus to replicate and infect new cells.
Integrase inhibitors are a novel class of HIV drugs aimed at a previously unexploited viral target. They are a key new class that will expand therapeutic options for HIV patients and stand out as one of the most promising emerging classes in development for HIV. The reported efficacy and safety data from clinical trials of Isentress indicate that the product is highly efficacious, safe, well tolerated in both treatment-naive and treatment-experienced HIV patients. The clinical data on Isentress presented to date suggests that there is significant opportunity for follow-on agents in this new class of HIV drugs.
Isentress is expected to launch during the fourth quarter of 2007, according to Merck.
Dr. Eash can provide:
- Insight on the class of integrase inhibitors and particularly Isentress and its potential effect on other drugs in the HIV market.
- Key factors that will have an impact on Isentress's uptake and use. How will Isentress be positioned in the lines of HIV treatment?
- The main drivers and barriers for its use. What is the forecast for Isentress? Which drugs will be its main competition?
- Key thought leaders' perceptions about Isentress.
- Isentress's impact on the HIV market and on the overall HIV therapeutic approach.
Sylvia Eash, Ph.D., is an analyst with Decision Resources Infectious Disease group, where she evaluates emerging therapies and develops market forecasts. She has a doctoral degree in pathobiology from . Dr. Eash is the author of several peer-reviewed primary literature and review articles, and she is a member of the American Society for Microbiology and the International Society of Neurovirology.
To talk with Dr. Eash, please contact Erica Ames at 781-296-2583 or . email@example.com
About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective firstname.lastname@example.org
CONTACT: Erica Ames of Decision Resources, +1-781-296-2583, email@example.com
Web site: http://www.decisionresources.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: October 2007
- FDA Approves New U.S. Labeling for Isentress (raltegravir) to Include 240-Week Results from STARTMRK Study of Isentress Containing Regimen in Previously Untreated HIV-1 Infected Adult Patient - July 2, 2013
- FDA Expands Use of HIV Drug Isentress to Children and Adolescents - December 21, 2011
- HIV/AIDS Update - Traditional Approval of Isentress (raltegravir) - February 5, 2009
- FDA Approves of Isentress (raltegravir) - October 12, 2007
- FDA Advisory Committee Unanimously Recommends Accelerated Approval of Isentress (raltegravir), Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIV - September 6, 2007
- FDA Priority Review Granted for Isentress (raltegravir), Merck's Investigational Integrase Inhibitor for HIV - June 27, 2007